Jaoko, WalterNakwagala, Frederick N.Anzala, OmuManyonyi, Gloria OmosaBirungi, JosephineNanvubya, AnnetOgutu, HildaWakasiaka, SabinaMatu, LucyOdada, JaneKonde, CarolMugisha, EmmanuelMuluubya, AndrewKaleebu, Pontiano2023-04-192023-04-192008Jaoko, W., Nakwagala, F. N., Anzala, O., Manyonyi, G. O., Birungi, J., Nanvubya, A., ... & Kaleebu, P. (2008). Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa. Vaccine, 26(22), 2788-2795.https://doi.org/10.1016/j.vaccine.2008.02.0710264-410Xhttps://nru.uncst.go.ug/handle/123456789/8524The safety and immunogenicity of plasmid pTHr DNA, modified vaccinia virus Ankara (MVA) human immunodeficiency virus type 1 (HIV-1) vaccine candidates were evaluated in four Phase I clinical trials in Kenya and Uganda. Both vaccines, expressing HIV-1 subtype A gag p24/p17 and a string of CD8 T-cell epitopes (HIVA), were generally safe and well-tolerated. At the dosage levels and intervals tested, the percentage of vaccine recipients with HIV-1-specific cell-mediated immune responses, assessed by a validated ex vivo interferon gamma (IFN-γ) ELISPOT assay and Cytokine Flow Cytometry (CFC), did not significantly differ from placebo recipients. These trials demonstrated the feasibility of conducting high-quality Phase 1 trials in Africa.enHumansmodified vaccinia virus Ankara (MVA)HIV-1 A vaccineArticle